ADAGIO Study Provides Evidence that GB-102 Can Achieve Sustained-Drug Delivery in the Treatment of Wet Age-Related Macular Degeneration (AMD) Graybug Vision’s novel investigational depot approach is designed to continuously inhibit activity of all VEGF receptors for the treatment of wet AMD GB-102 was well-tolerated with no dose limiting toxicities, drug-related serious adverse events or inflammation […]
https://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.png00retinalconsultantshttps://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.pngretinalconsultants2019-01-21 22:12:512021-03-25 06:34:36Graybug Vision Presents Top Line Results Of Phase 1/2a ADAGIO Study At Hawaiian Eye & Retina 2019
An Independent Analysis of Protocol i Study Data Dugel, Pravin U., MD*,†; Campbell, Joanna H., PhD‡; Kiss, Szilárd, MD§; Loewenstein, Anat, MD¶; Shih, Vanessa, PharmD‡; Xu, Xiaoshu, MS‡; Holekamp, Nancy M., MD**; Augustin, Albert J., MD, PhD††; Ho, Allen C., MD‡‡; Gonzalez, Victor H., MD§§; Whitcup, Scott M., MD¶¶ RETINA: January 2019 – Volume 39 […]
https://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.png00retinalconsultantshttps://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.pngretinalconsultants2019-01-02 23:24:412019-01-02 23:24:41Pravin U. Dugel, MD: Association Between Early Anatomic Responses to Anti-Vascular Endothelial Growth Factor Therapy and Long-term Outcome in Diabetic Macular Edema
Neovascular age-related macular degeneration (nAMD) is the leading cause of severe vision loss and irreversible blindness in people aged over 65 years in North America, Europe, Australia, and Asia.1 Anti-vascular endothelial growth factor (anti-VEGF) therapies have led to great improvements in outcomes for patients with nAMD.2 However, currently available anti-VEGF treatments require frequent clinic visits to monitor […]
https://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.png00retinalconsultantshttps://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.pngretinalconsultants2018-11-30 23:11:482018-11-30 23:11:48Dr. Pravin U. Dugel: Brolucizumab in the Treatment of Neovascular Age-Related Macular Degeneration
Retina Subspecialty Day Coverage – American Academy of Ophthalmology 2018 Series: 2018 Pravin U. Dugel, MD Channels: Retina Pravin U. Dugel, MD, details the results of the phase 3 HAWK and HARRIER studies evaluating brolucizumab (Novartis) for the treatment of wet age-related macular degeneration. Dr. Dugel compares data from the 96-week endpoint to the […]
https://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.png00retinalconsultantshttps://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.pngretinalconsultants2018-11-07 22:47:432018-11-07 22:47:43Dr. Pravin U. Dugel: Anatomy in HAWK and HARRIER
October 27, 2018 10:09 ET | Source: Novartis International AG Year two results consistent with previously announced key secondary endpoint data on retinal fluid (IRF and/or SRF) showing superior reductions versus aflibercept Superior reductions in central subfield thickness demonstrated at year one were reaffirmed at year two with brolucizumab 6 mg versus aflibercept Robust visual gains shown in […]
https://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.png00retinalconsultantshttps://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.pngretinalconsultants2018-10-28 12:47:302018-10-28 12:47:30Dr. Pravin U. Dugel: Two-year data for Novartis brolucizumab reaffirm superiority versus aflibercept in reducing retinal fluid in patients with nAMD
At this year’s EURETINA congress, we caught up with Dr Pravin Dugel to discuss neovascular age-related macular degeneration (nAMD). Dr Dugel suggests that while there have been recent advances in the treatment of nAMD, there is still a need to obtain better efficacy and find drugs that maintain visual acuity improvement over the […]
https://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.png00retinalconsultantshttps://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.pngretinalconsultants2018-10-21 22:32:222018-10-21 22:32:22Pravin U. Dugel, MD At EURETINA 2018: Brolucizumab For Neovascular Age-Related Macular Degeneration
Lausanne, Switzerland, September 24th, 2018 – Oculis, a clinical-stage biotechnology company developing next-generation topical treatments for acute and chronic back- and front-of-the-eye diseases, announces the appointment of Pravin U. Dugel, M.D. as Chairman of its Scientific Advisory Board (SAB). Dr. Dugel is internationally recognized for his research in the field of ophthalmologic diseases and brings […]
https://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.png00retinalconsultantshttps://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.pngretinalconsultants2018-09-25 03:12:272018-09-25 03:12:27Oculis appoints World-renowned Ophthalmology Specialist Pravin U. Dugel, M.D. as Chairman of its Scientific Advisory Board
PALO ALTO, Calif., Aug. 31, 2018 /PRNewswire/ — Kodiak Sciences Inc., a clinical stage biopharmaceutical company specializing in novel therapeutics to treat high prevalence ophthalmic diseases, today announced that enrollment of patients in the company’s phase 1 safety and tolerability study has been completed. First patient in was dosed on July 12, 2018 and last patient […]
https://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.png00retinalconsultantshttps://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.pngretinalconsultants2018-09-01 00:25:392018-09-01 00:25:39Dr. Pravin Dugel: Kodiak Sciences Announces Completion of Enrollment in the Company’s Phase 1 Safety and Tolerability Study in Patients with Retinal Disease
We are pleased to share that the first patient in Kodiak’s phase I trial was treated by Dr. Pravin Dugel of the Retinal Consultants of Arizona. The injection was uneventful. Day 2 assessment was within normal limits with no signs of inflammation and with clear ocular media. Kodiak is A Phase I Open Label, Multi-center […]
https://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.png00retinalconsultantshttps://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.pngretinalconsultants2018-07-14 14:20:272018-07-14 14:20:27Dr. Pravin U. Dugel Treats First Patient with KSI-301
Dr. Derek Kunimoto visits the AZTV studios to discuss CentraSight’s Implantable Telescope for people with end-stage macular degeneration (wet and dry). For more information, call 602-222-2221 or visit www.CentraSight.com. Age-related macular degeneration (AMD) is the most common cause of severe vision loss in patients over 65. This condition involves a breakdown of the macula, the central […]
Graybug Vision Presents Top Line Results Of Phase 1/2a ADAGIO Study At Hawaiian Eye & Retina 2019
/ Uncategorized /by retinalconsultantsADAGIO Study Provides Evidence that GB-102 Can Achieve Sustained-Drug Delivery in the Treatment of Wet Age-Related Macular Degeneration (AMD) Graybug Vision’s novel investigational depot approach is designed to continuously inhibit activity of all VEGF receptors for the treatment of wet AMD GB-102 was well-tolerated with no dose limiting toxicities, drug-related serious adverse events or inflammation […]
Pravin U. Dugel, MD: Association Between Early Anatomic Responses to Anti-Vascular Endothelial Growth Factor Therapy and Long-term Outcome in Diabetic Macular Edema
/ Uncategorized /by retinalconsultantsAn Independent Analysis of Protocol i Study Data Dugel, Pravin U., MD*,†; Campbell, Joanna H., PhD‡; Kiss, Szilárd, MD§; Loewenstein, Anat, MD¶; Shih, Vanessa, PharmD‡; Xu, Xiaoshu, MS‡; Holekamp, Nancy M., MD**; Augustin, Albert J., MD, PhD††; Ho, Allen C., MD‡‡; Gonzalez, Victor H., MD§§; Whitcup, Scott M., MD¶¶ RETINA: January 2019 – Volume 39 […]
Dr. Pravin U. Dugel: Brolucizumab in the Treatment of Neovascular Age-Related Macular Degeneration
/ Uncategorized /by retinalconsultantsNeovascular age-related macular degeneration (nAMD) is the leading cause of severe vision loss and irreversible blindness in people aged over 65 years in North America, Europe, Australia, and Asia.1 Anti-vascular endothelial growth factor (anti-VEGF) therapies have led to great improvements in outcomes for patients with nAMD.2 However, currently available anti-VEGF treatments require frequent clinic visits to monitor […]
Dr. Pravin U. Dugel: Anatomy in HAWK and HARRIER
/ Uncategorized /by retinalconsultantsRetina Subspecialty Day Coverage – American Academy of Ophthalmology 2018 Series: 2018 Pravin U. Dugel, MD Channels: Retina Pravin U. Dugel, MD, details the results of the phase 3 HAWK and HARRIER studies evaluating brolucizumab (Novartis) for the treatment of wet age-related macular degeneration. Dr. Dugel compares data from the 96-week endpoint to the […]
Dr. Pravin U. Dugel: Two-year data for Novartis brolucizumab reaffirm superiority versus aflibercept in reducing retinal fluid in patients with nAMD
/ AAO /by retinalconsultantsOctober 27, 2018 10:09 ET | Source: Novartis International AG Year two results consistent with previously announced key secondary endpoint data on retinal fluid (IRF and/or SRF) showing superior reductions versus aflibercept Superior reductions in central subfield thickness demonstrated at year one were reaffirmed at year two with brolucizumab 6 mg versus aflibercept Robust visual gains shown in […]
Pravin U. Dugel, MD At EURETINA 2018: Brolucizumab For Neovascular Age-Related Macular Degeneration
/ Uncategorized /by retinalconsultants At this year’s EURETINA congress, we caught up with Dr Pravin Dugel to discuss neovascular age-related macular degeneration (nAMD). Dr Dugel suggests that while there have been recent advances in the treatment of nAMD, there is still a need to obtain better efficacy and find drugs that maintain visual acuity improvement over the […]
Oculis appoints World-renowned Ophthalmology Specialist Pravin U. Dugel, M.D. as Chairman of its Scientific Advisory Board
/ Uncategorized /by retinalconsultantsLausanne, Switzerland, September 24th, 2018 – Oculis, a clinical-stage biotechnology company developing next-generation topical treatments for acute and chronic back- and front-of-the-eye diseases, announces the appointment of Pravin U. Dugel, M.D. as Chairman of its Scientific Advisory Board (SAB). Dr. Dugel is internationally recognized for his research in the field of ophthalmologic diseases and brings […]
Dr. Pravin Dugel: Kodiak Sciences Announces Completion of Enrollment in the Company’s Phase 1 Safety and Tolerability Study in Patients with Retinal Disease
/ Uncategorized /by retinalconsultantsPALO ALTO, Calif., Aug. 31, 2018 /PRNewswire/ — Kodiak Sciences Inc., a clinical stage biopharmaceutical company specializing in novel therapeutics to treat high prevalence ophthalmic diseases, today announced that enrollment of patients in the company’s phase 1 safety and tolerability study has been completed. First patient in was dosed on July 12, 2018 and last patient […]
Dr. Pravin U. Dugel Treats First Patient with KSI-301
/ Uncategorized /by retinalconsultantsWe are pleased to share that the first patient in Kodiak’s phase I trial was treated by Dr. Pravin Dugel of the Retinal Consultants of Arizona. The injection was uneventful. Day 2 assessment was within normal limits with no signs of inflammation and with clear ocular media. Kodiak is A Phase I Open Label, Multi-center […]
Dr. Derek Kunimoto Discusses the CentraSight Implantable Telescope – AZTV Phoenix
/ Uncategorized /by retinalconsultantsDr. Derek Kunimoto visits the AZTV studios to discuss CentraSight’s Implantable Telescope for people with end-stage macular degeneration (wet and dry). For more information, call 602-222-2221 or visit www.CentraSight.com. Age-related macular degeneration (AMD) is the most common cause of severe vision loss in patients over 65. This condition involves a breakdown of the macula, the central […]